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ORIGINAL ARTICLE
Loss of PRDM1/BLIMP-1 function contributes to poor
prognosis of activated B-cell-like diffuse large B-cell
lymphoma
Y Xia1,2,24, ZY Xu-Monette1,24, A Tzankov3,24, X Li1, GC Manyam4, V Murty5, G Bhagat5, S Zhang1, L Pasqualucci5, C Visco6, K Dybkaer7,
A Chiu8, A Orazi9, Y Zu10, KL Richards11, ED Hsi12, WWL Choi13, JH van Krieken14, J Huh15, M Ponzoni16, AJM Ferreri16, MB Møller17,
BM Parsons18, JN Winter19, MA Piris20, J Westin21, N Fowler21, RN Miranda1, CY Ok1, Y Li22, J Li2, LJ Medeiros1 and KH Young1,23
PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell
lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with
de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was
frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients
were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased
expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which
encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but
not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression proﬁling revealed that loss of PRDM1/BLIMP-1
expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling
and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of
PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of
ABC-DLBCL patients.
Leukemia (2017) 31, 625–636; doi:10.1038/leu.2016.243
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type
of lymphoid malignancy, accounting for 30–40% of all non-
Hodgkin lymphoma.1 Anthracycline-based combination che-
motherapy, ﬁrst introduced in the 1970 s, is the backbone of
therapy for patients with DLBCL, and currently the standard
therapy regimen includes the anti-CD20 antibody rituximab plus
cyclophosphamide, doxorubicin, vincristine and prednisone.2–4
Despite encouraging complete remission and overall survival (OS)
rates using this regimen, up to one-third of DLBCL patients suffer
from relapse or refractory primary disease.5
The heterogeneous clinical outcome of DLBCL results in part
from variable genetic proﬁles of this tumor. Gene expression
proﬁling (GEP) has identiﬁed two distinct types of DLBCL: germinal
center B-cell-like and activated B-cell-like (GCB and ABC). Patients
with ABC-DLBCL have markedly poorer survival than do patients
with GCB-DLBCL.6,7 However, the molecular mechanism respon-
sible for this difference is not completely understood.
ABC-DLBCL is characterized by constitutive nuclear factor-κB
(NF-κB) activation and genetic alterations that interfere with
terminal B-cell differentiation.8 PRDM1, located on chromosome
6q21, encodes for BLIMP-1, a zinc-ﬁnger-containing DNA-binding
transcriptional repressor. BLIMP-1 expression is required for the
development of immunoglobulin-secreting cells and maintenance
of long-lived plasma cells.9 Conditional PRDM1-knockout mice do
not have production of plasma cells or serum immunoglobulins.10
PRDM1 is frequently inactivated in ABC-DLBCL cases as a result
of genetic deletions or mutations or transcriptional repression of
it.11,12 Studies have demonstrated that an inactivation mutation of
PRDM1 is recurrent in ~ 25% of ABC-DLBCL cases.11–14 Moreover,
conditional deletion of PRDM1 in murine B cells facilitates the
development of lymphoproliferative disease resembling human
ABC-DLBCL.8,11
Limited research has been carried out on the clinical implica-
tions of PRDM1/BLIMP-1 abnormality in DLBCL patients. In the
present study, we investigated PRDM1 deletion and mutation and
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BLIMP-1 protein expression in a large cohort of de novo DLBCL
patients treated with rituximab plus cyclophosphamide, doxor-
ubicin, vincristine and prednisone. Our results demonstrated that
disruption of PRDM1/BLIMP-1 is associated with poor prognosis for
ABC-DLBCL. We further characterized the potential molecular
mechanisms underlying the tumor-suppressive function of
PRDM1/BLIMP-1 using GEP.
MATERIALS AND METHODS
Patients
We studied 520 biopsy specimens obtained from rituximab plus cyclopho-
sphamide, doxorubicin, vincristine and prednisone-treated patients with de
novo DLBCL. The diagnostic criteria for DLBCL, patient-selection process,
therapy and treatment responses were described previously.15 The study
was approved by the institutional review boards of the participating
institutions.
Immunohistochemistry
Tissue microarrays prepared using formalin-ﬁxed, parafﬁn-embedded
tissue blocks of the diagnostic biopsy specimens obtained from the
studied patients were stained with an anti-BLIMP-1 antibody (EPR16655;
Epitomics, Burlingame, CA, USA). BLIMP-1 expression levels were
determined by estimating the percentage of BLIMP-1+ tumor cells in the
tissue sections. Evaluation of other biomarkers was performed using
immunohistochemistry with corresponding antibodies. Details of the
immunohistochemical procedures and scoring processes were described
previously.15–19
Fluorescence in situ hybridization, and PRDM1 and TP53
sequencing
Fluorescence in situ hybridization (FISH) probes spanning the PRDM1 gene
and chromosome 6 centromere were generated as described previously.13
Dual-color FISH was performed using standard procedures. Brieﬂy, 4-μm-
thick tissue sections were baked overnight at 56 °C, deparafﬁnized in
CitriSolv, treated with 0.2 N hydrochloric acid for 20 min at room
temperature, pretreated with 1 N sodium thiocyanate at 80 °C for 30 min,
protease-digested at 37 °C for 50 min, reﬁxed in 10% buffered formalin for
10 min and derehydrated in a 70, 85 and 100% ethanol series before
hybridization. The tissue sections were codenatured with the addition of a
probe for 8 min at 74 °C and incubated for 24 h at 37 °C in a hybridization
oven (ThermoBrite, Buffalo Grove, IL, USA). Posthybridization washes were
performed in 0.4x standard saline citrate/0.3% NP-40 for 2 min and 2x
standard saline citrate/0.1% NP-40 for 1 min at 72 °C. Slides were then
mounted with 4,6-diamidino-2-phenylindole (0.5 g/ml) containing an
antifade solution. For one slide containing 25 cases, 200 nuclei of cells
were evaluated independently by two observers (AT and VM). The overall
concordance of their evaluations was nearly perfect (κ= 0.95), thus all
other slides (200 nuclei per case) were scored by AT only. The ratio of
PRDM1 signals (red) to CEP6 signals (green) was calculated. If this ratio was
lower than 0.72, heterozygous PRDM1 deletion was considered to be
present. Ratios lower than 0.38 were considered to be suggestive of
homozygous PRDM1 deletions. These ratios were calculated as ratios below
the mean plus three standard deviations of green to red signal ratios in
reference cases (tonsils; n=6) and subtraction of tumor-inﬁltrating T cells,
which accounted for ~ 30% of undeleted alleles. MYC, BCL2 and BCL6 gene
arrangements and copy-number aberrations were detected using FISH, as
well.16,20
Sequencing of PRDM1 coding regions was performed by Polymorphic
DNA Technologies (Alameda, CA, USA) using Sanger sequencing.
Sequencing results were compared with the NCBI NM_001198
reference sequence, followed by exclusion of all the single-nucleotide
polymorphisms documented by the NCBI dbSNP database (build 147).
The remaining variates detected by sequencing were considered as
PRDM1 somatic mutations. TP53 was sequenced using a p53 AmpliChip
(Roche Molecular Diagnostics, Pleasanton, CA, USA) as described
previously.21
GEP and GCB/ABC classiﬁcation
GEP was performed using a GeneChip Human Genome U133 Plus 2.0 Array
(Affymetrix, Santa Clara, CA, USA) with total RNAs as described
previously.15,21 The CEL ﬁles were deposited in the National Center for
Biotechnology Information Gene Expression Omnibus repository (GSE no.
31312). GEP classiﬁed 407 cases as GCB/ABC subtypes, and the cell of
origin of another 111 cases was determined and compared by
immunohistochemical algorithms (Hans, Visco-Young and Choi).15 Cell-of-
origin classiﬁcation based on B-cell-associated gene signatures has been
described previously.22
MicroRNA proﬁling
An HTG EdgeSeq Whole Transcriptome Assay (HTG Molecular Diagnos-
tics, Tucson, AZ, USA) coupled with a HiSeq system (Illumina, San Diego,
CA, USA) was used for measuring the expression of microRNAs (miRNAs)
in formalin-ﬁxed, parafﬁn-embedded tissues (unpublished data). Selec-
tion of regulatory miRNAs for BLIMP-1 expression was based on
TargetScan and published data.23–27
Statistical analysis
Clinical and molecular features of patient tumors were compared using the
Fisher's exact or χ2 test. OS and progression-free survival (PFS) in the study
population were analyzed using the Kaplan–Meier method, and differ-
ences between DLBCL subgroups were compared using the log-rank test
with the Prism 6 software program (GraphPad Software, San Diego, CA,
USA). Multivariate analysis was performed using the Cox proportional
hazards regression model with the SPSS software program (version 19.0;
IBM Corporation, Armonk, NY, USA). P-values of up to 0.05 were considered
statistically signiﬁcant.
RESULTS
Patients
The clinical characteristics of the study patients with DLBCL
(n= 520) are summarized in Table 1. Their median age was 65
years (range, 16–82 years), the median follow-up duration was
46.7 months (range, 20.0–186.7 months) and the male:female ratio
was 1.2:1. Two hundred sixty-eight patients (52%) had GCB-DLBCL,
and 250 patients (48%) had ABC-DLBCL.
Homozygous PRDM1 deletion predicts poor prognosis
for ABC-DLBCL
We detected homozygous deletion of PRDM1 in 19 (7%) of 292
patients with available FISH results (Figure 1a and Supplementary
Table 1). Patients with homozygous PRDM1 deletions had lower
BLIMP-1 protein expression than did those without these deletions
(P= 0.055; Figure 1a). Homozygous PRDM1 deletion was not
associated with the ABC phenotype (P= 0.34) or any other clinical
parameters. OS was signiﬁcantly shorter in patients with homo-
zygous PRDM1 deletions than in those with normal or hetero-
zygous deletions of PRDM1 or monosomy 6 (P= 0.037) (Figure 1b).
This difference was remarkable in patients with ABC-DLBCL
(P= 0.004) but not in those with GCB-DLBCL (P= 0.98)
(Figure 1b). Homozygous PRDM1 deletion was also associated
with signiﬁcantly poorer PFS in the entire DLBCL cohort
(P= 0.0048) and in ABC-DLBCL (P= 0.036) (Figure 1c). Multivariate
analysis adjusting clinical features conﬁrmed homozygous PRDM1
deletion as an independent prognostic factor for both OS
(P= 0.032) and PFS (P= 0.037). In the ABC-DLBCL patients,
homozygous PRDM1 deletion was an independent prognostic
factor for OS (P= 0.032) but not for PFS (P= 0.13) (Table 2).
PRDM1 mutation predicts poor prognosis for ABC-DLBCL
We studied PRDM1 mutations in 368 patients with available
genomic DNA. Using a quality score cutoff of 16 (97% conﬁ-
dence), we identiﬁed that 94 patients (25.5%) had PRDM1
mutations within the coding DNA sequence region of PRDM1
(Supplementary Table 2). Of these, seven patients had truncating
(nonsense) mutations and two had a frameshift mutation. Seven
of these nine patients had ABC-DLBCL, including four patients
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with short OS and PFS (Supplementary Table 3). PRDM1 mutation
was not associated with the ABC phenotype (P= 0.91) and did not
impact survival in the overall cohort or in GCB-DLBCL patients in
particular (Supplementary Figure 1). However, PRDM1 mutation
did correlate with poorer prognosis for ABC-DLBCL (Figure 2a).
Moreover, ABC-DLBCL patients harboring PRDM1 mutations within
exon 1 or 2 had markedly shorter survival durations than did
patients with mutations in exons 3–7 or wild-type PRDM1
(Figures 2b and c). In comparison, the prognostic impact of exon
1 and 2 PRDM1 mutations on GCB-DLBCL was minimal
(Supplementary Figure 2). Consistently, we found that patients
with exon 1 and 2 PRDM1 mutations were more likely to
have overexpression of both Myc and Bcl-2 than were patients
with exon 3–7 mutations in the overall cohort (P= 0.03) and
those with wild-type PRDM1 in ABC-DLBCL (P= 0.05) but not in
those with GCB-DLBCL (P= 0.44). Multivariate analysis of clinical
parameters, Myc/Bcl-2 expression scores, and PRDM1 mutations
indicated that Myc/Bcl-2 coexpression (hazard ratio: 2.9,
Po0.001), but not PRDM1 mutations (hazard ratio: 1.54,
P= 0.12), was an independent prognostic factor in ABC-DLBCL.
Table 1. Clinical features of DLBCL patients with BLIMP-1 expression, PRDM1 mutation and homozygous deletion
Variables BLIMP-1 protein expression PRDM1 mutation Homozygous PRDM1 deletion
Positive Negative P-value Positive Negative P-value Positive Negative P-value
No. of patients 132 388 94 274 19 273
Cell-of-origin
GCB 39 (30%) 229 (59%) o0.0001 48 (51%) 141 (52%) 0.91 7 (37%) 138 (51%) 0.34
ABC 92 (70%) 158 (41%) 46 (49%) 131 (48%) 12 (63%) 134 (49%)
Plasmablastic subtype
No 55 (47%) 259 (94%) o0.0001 25 (80%) 48 (87%) 0.41 9 (100%) 185 (87%) 0.27
Yes 29 (53%) 15 (6%) 6 (20%) 7 (13%) 0 25 (13%)
Age (years)
o60 53 (40%) 166 (43%) 0.61 39 (41%) 117 (43%) 0.90 10 (53%) 114 (42%) 0.47
⩾ 60 79 (60%) 222 (57%) 55 (59%) 157 (57%) 9 (47%) 159 (58%)
Gender
Male 81 (61%) 224 (58%) 0.46 51 (54%) 162 (59%) 0.47 11 (58%) 143 (52%) 0.81
Female 51 (39%) 164 (42%) 43 (46%) 112 (41%) 8 (42%) 130 (48%)
Stage
I and II 60 (47%) 179 (47%) 0.96 36 (41%) 120 (45%) 0.54 11 (58%) 126 (48%) 0.48
III and IV 67 (53%) 198 (53%) 52 (59%) 147 (55%) 8 (42%) 135 (52%)
B symptoms
No 78 (61%) 244 (67%) 0.24 48 (55%) 176 (68%) 0.039 15 (79%) 165 (63%) 0.22
Yes 50 (39%) 122 (33%) 39 (45%) 84 (32%) 4 (21%) 98 (37%)
LDH level
Normal 49 (41%) 134 (38%) 0.58 30 (34%) 107 (43%) 0.17 8 (44%) 102 (40%) 0.80
Elevated 72 (59%) 222 (62%) 57 (66%) 140 (57%) 10 (56%) 156 (60%)
No. of extranodal sites
0–1 93 (74%) 287 (77%) 0.51 65 (72%) 200 (77%) 0.39 17 (94%) 197 (78%) 0.13
⩾ 2 33 (26%) 87 (23%) 25 (28%) 59 (23%) 1 (6%) 57 (22%)
ECOG performance status
0–1 99 (84%) 289 (83%) 0.83 61 (72%) 208 (86%) 0.005 16 (89%) 204 (83%) 0.75
⩾ 2 19 (16%) 59 (17%) 24 (28%) 34 (14%) 2 (11%) 43 (17%)
Size of largest tumor (cm)
o5 61 (64%) 162 (56%) 0.19 38 (61%) 129 (59%) 0.88 10 (67%) 129 (54%) 0.43
⩾ 5 35 (36%) 128 (44%) 24 (39%) 88 (41%) 5 (33%) 108 (46%)
IPI score
0–2 77 (59%) 231 (62%) 0.59 50 (54%) 166 (63%) 0.14 13 (68%) 160 (61%) 0.51
3–5 53 (41%) 142 (38%) 42 (46%) 96 (37%) 6 (32%) 103 (39%)
Therapy response
CR 103 (78%) 286 (74%) 0.32 65 (69%) 206 (75%) 0.28 14 (74%) 214 (78%) 0.58
PR 17 (13%) 52 (13%) 18 (19%) 35 (13%) 4 (21%) 29 (11%)
SD 6 (4.5%) 18 (5%) 4 (4%) 12 (4%) 1 (5%) 11 (4%)
PD 6 (4.5%) 32 (8%) 7 (7%) 21 (8%) 0 19 (7%)
Abbreviations: ABC, activated B-cell-like; CR, complete response; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB,
germinal center B-cell-like; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial response; SD, stable disease.
Bold values are the signiﬁcant P values or those showing trends of signiﬁcance.
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We also studied the correlations between various types of
PRDM1 mutations and BLIMP-1 protein expression, as well as
PRDM1 deletion. Patients with nonsense mutations or exon 1/2
mutations had lower BLIMP-1 expression than patients without
these aberrations, but the P-values for the differences were not
signiﬁcant (Supplementary Figure 3). No signiﬁcant associations
were observed between PRDM1 mutations and PRDM1 allelic
deletions.
Heterozygous deletion Homozygous deletion Monosomy 6
MonthsMonthsMonths
Figure 1. Homozygous PRDM1 deletion in DLBCL cases. (a) Representative examples of FISH results with heterozygous PRDM1 deletion (of
note are a mixture of cells with two green signals, corresponding to centromere 6, but lacking red signals, corresponding to PRDM1, and cells
with two green signals and one red signal), homozygous PRDM1 deletion (of note are two green signals but a lack of red signals in the
majority of the cells; one cell in the center of the microphotograph has both red and green signals and serves as an internal positive control)
and monosomy 6 (all cells have only one green and one red signal). DLBCL patients with homozygous PRDM1 deletions had lower levels of
BLIMP-1 protein expression than did the rest of the studied patients. (b and c) The impact of homozygous PRDM1 deletion on OS and PFS in
all patients with DLBCL, patients with ABC-DLBCL and patients with GCB-DLBCL. Patients with this deletion had shorter OS and PFS durations
than did patients with normal FISH signals, heterozygous PRDM1 deletions or monosomy 6. This trend was greater in patients with ABC-DLBCL
than in GCB-DLBCL.
Table 2. Multivariate analysis for homozygous PRDM1 deletions in DLBCL and ABC-DLBCL
DLBCL ABC-DLBCL
Overall survival Progression-free survival Overall survival Progression-free survival
P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI
Female sex 0.60 0.89 0.58–1.37 0.69 0.92 0.62–1.37 0.63 1.15 0.66–1.99 0.71 1.10 0.67–1.82
B symptoms 0.031 1.62 1.04–2.50 0.072 1.45 0.97–2.19 0.26 1.37 0.79–2.37 0.21 1.39 0.83–2.32
IPI42 o0.001 3.02 1.96–4.64 o0.001 2.62 1.76–3.89 o0.001 2.67 1.57–4.53 0.001 2.29 1.40–3.75
Tumor size 45 cm 0.18 1.33 0.87–2.02 0.56 1.12 0.64–1.66 0.26 1.35 0.80–2.26 0.60 1.14 0.70–1.84
PRDM1 homozygous deletion 0.032 2.23 1.07–4.65 0.037 2.09 1.05–4.18 0.032 2.58 1.08–6.15 0.13 1.95 0.83–4.59
Abbreviations: ABC, activated B-cell like; HR, hazard ratio; CI, conﬁdence interval; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index. Bold
values are the signiﬁcant P values or those showing trends of signiﬁcance.
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Loss of BLIMP-1 protein expression correlates with Myc
overexpression and decreased p53 pathway molecule expression
in ABC-DLBCLs
Representative immunohistochemical staining of formalin-ﬁxed,
parafﬁn-embedded tissue sections for BLIMP-1 protein expression
is shown in Figure 3a. Using a cutoff of 10%, we found that 132
(25%) of the 520 patients were positive for BLIMP-1. BLIMP-1
protein expression was more common in patients with the ABC
phenotype (37% vs 15% in GCB-DLBCL, Po0.0001) and plasma-
blast subtype22 of DLBCL than others (Po0.0001; Table 1). The
histogram of BLIMP-1 expression in the study cohort, and
distribution of PRDM1 deletions and mutations and BLIMP-1
protein expression in 180 patients with all data available is shown
in Figure 3b. Ninety-six of these patients were in the ABC
subgroup, 59 of whom (61%) had BLIMP-1− DLBCL. Thirty-seven
(63%) of the BLIMP-1−ABC-DLBCL cases had no detectable PRDM1
deletions or mutations. MiRNA proﬁling identiﬁed that miR-30d-
3p, miR-30d-5p and miR-30b-5p were signiﬁcantly upregulated in
BLIMP-1− patients without apparent PRDM1 genetic aberrations,
suggesting that epigenetic regulations may also have a role in loss
of PRDM1/BLIMP-1 expression.
In the ABC subgroup, BLIMP-1 negativity was associated with
reduced protein expression for the NF-κB pathway component
p65 (P= 0.028), p53 (P= 0.024; only in subjects wild type for P53),
p53 downstream targets MDM2 (P= 0.002) and p21 (P= 0.074),
and phosphorylated AKT (P= 0.0095). BLIMP-1 negativity also was
more common in patients without expression of CD30 (P= 0.0082)
(Table 3). Of note, Myc expression was increased in BLIMP-1−
cases, with a trend of signiﬁcance (P= 0.085), and this negative
correlation between BLIMP-1 and Myc overexpression in ABC-
DLBCL was statistically signiﬁcant when using a higher cutoff
(⩾20%) for BLIMP-1+ (P= 0.0062).
In the GCB subgroup, BLIMP-1 negativity was associated with
MYC translocation (P= 0.049), mutated p53 overexpression, and
decreased p21 expression (P= 0.0028) (Table 3). We found several
other alterations associated with BLIMP-1 negativity in the overall
DBLCL cohort, including BCL2 translocation (P= 0.004), TP53
mutation (P= 0.005), decreased expression of p63 (P= 0.023),
nuclear p50 (P= 0.023) and IRF4/MUM1 (Po0.0001), increased
expression of GCET1 (P= 0.039) and CD10 (P= 0.019), and a lack of
BCL6 translocation. Bcl-6 expression tended to be upregulated in
BLIMP-1− DLBCLs (P= 0.092), especially in patients with mutated
TP53 (P= 0.075).
We did not observe correlations between BLIMP-1 expression
and survival in the study cohort (Supplementary Figure 4).
However, BLIMP-1 negativity had an unfavorable impact on OS
and PFS in DLBCL patients with TP53 mutations, although the
impact was not signiﬁcant (OS, P= 0.12; PFS, P= 0.074) (Figure 3c).
ABC        GCB
regnif-nZorPRPcidicA Acidic
Exon 2Exon 1
0
1
2
3
4
5C 12T 23T 31E 32G 33T 34K 37M 39M 43D 45D 55E 56E 62V 66P 67W 70G 76S 81A 84P 87L 91Y 93T 96E 97E
Months Months
Figure 2. Correlation of PRDM1 mutations with poor prognosis for DLBCL. (a) In ABC-DLBCL, patients with PRDM1 mutations had shorter OS
and PFS durations than did patients with wild-type PRDM1. (b) PRDM1 mutations within exons 1 and 2 had even greater poor impact on OS
and PFS compared with the overall mutation cohort. (c) The detailed distribution of PRDM1 mutations within exons 1 and 2.
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Homozygous PRDM1 deletion contributes to gene expression
signatures of transcriptional activation
We identiﬁed 25 differentially expressed genes (DEGs) between
homozygous PRDM1 deletion-positive and -negative DLBCL cases
(Figure 4a). Expression of all of the DEGs was upregulated.
Subjects with homozygous PRDM1 deletions had robust transcrip-
tional activity with upregulation of transcription factors STAT3,
HLF, TCF19, TSHZ1 and HMGA2. Accordingly, analysis of the ABC
BLIMP-1+ ABCABC
MonthsMonths
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Figure 3. BLIMP-1 protein expression in DLBCL. (a) Representative immunohistochemical stains of DLBCL sections for BLIMP-1 protein
expression. (b) The histograms of BLIMP-1 protein expression in all DLBCL patients, and the distribution of PRDM1 deletions and mutations
and BLIMP-1 protein expression in 180 patients with all these three data available. Expression of miR-30d-3p and miR-30b-5p was elevated in
BLIMP-1− DLBCL patients without PRDM1 genetic alterations. (c) The impact of BLIMP-1 protein expression on OS and PFS in DLBCL patients
with mutated TP53.
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subgroup also identiﬁed increased transcriptional signatures
(Table 4). In contrast, we found no DEGs for homozygous PRDM1
deletion in the GCB subgroup.
BLIMP-1 expression signatures in the overall cohort resemble
those in ABC-DLBCL
We compared GEP of BLIMP-1− and BLIMP-1+ DLBCL cases in the
overall DLBCL cohort, in wild-type and mutated PRDM1 subsets
(Figure 4a). DEGs were identiﬁed in the overall DLBCL and the
subset with wild-type PRDM1 (147 and 32 DEGs, respectively, with
a false discovery rate (FDR) threshold of 0.01), but not in the
subset with mutated PRDM1, suggesting loss of wild-type BLIMP-1
function (Table 4). Loss of BLIMP-1 expression in DLBCL was
associated with downregulation of PRDM1, X-box binding protein
1 (XBP1), which encodes for a critical regulator of plasma
differentiation,28 and its downstream target genes involved in
endoplasmic reticulum, protein synthesis and transportation.29,30
Moreover, expression of genes related to immunoglobulin
production (ELL2, MGC29506/MZB1 and ARID3A), cell differentia-
tion (BATF, IRF4, which transactivates PRDM1 and represses BCL6
expression31) and B/T cell receptor signaling inhibition (LAX1)
was also downregulated in BLIMP-1− DLBCLs. In contrast,
expression of CD22, MS4A1, which encodes for CD20, BCL11A
(a B-cell proto-oncogene and cofactor with Bcl-6, upregulated
during hematopoietic cell differentiation) and BLK, which is
involved in B-cell receptor (BCR) signaling was markedly
upregulated (1.42-, 1.54-, 1.67- and 1.2-fold, respectively).
DEGs were also identiﬁed in the ABC and GCB subgroups (38
DEGs in ABC with an FDR threshold of 0.05 (Table 4); 22 DEGs in
GCB with an FDR threshold of 0.15; Supplementary Table 4). When
analyzed in the wild-type and mutated PRDM1 subsets separately,
DEGs were only identiﬁed in ABC-DLBCL (but not GCB-DLBCL) with
wild-type PRDM1 (30 DEGs with a FDR threshold of 0.30; Figure 4a
and Table 4). The spectrum of DEGs in the ABC subgroup was
similar to that in the overall cohort, including downregulation of
PRDM1, XBP1, GHITM, DUSP4, TMEM59, APOBEC3B, FKBP11, DNAJC3,
DNAJB9, MANF, SEC24A, VDR, TXNDC5, ITGAL and C12orf55, as well
as upregulation of BCL11A, CD22 and CLLU1 in BLIMP-1− ABC-
DLBCL cases. IGJ was downregulated in BLIMP-1− ABC-DLBCL,
whereas CD37 antigen was upregulated. In comparison, the DEGs
identiﬁed in the overall GCB-DLBCL (regardless of PRDM1
mutation status) also included PRDM1, BCL11A and DUSP4, but
were more likely to be involved in immune responses (CTLA4,
GBP5, C1orf38, HLA-F and SERPINB1) and metabolism (ACSL1,
LPCAT2, GTPBP8, CTSA and METRNL) (Supplementary Figure 5a).
Considering the potential prognostic impact of BLIMP-1
expression in DLBCL patients with mutated TP53, we additionally
compared the BLIMP-1 expression signatures in patients with
mutated TP53 and in those wild type for TP53. Forty-three and 33
DEGs were identiﬁed, respectively, in these two subsets with an
FDR threshold of 0.20 (Supplementary Figures 5b–c and
Supplementary Table 4). Comparing these two BLIMP-1 GEP
signatures, we found that PRDM1, SSR1 and HSP90B1 were
common signatures. Unique BLIMP-1 expression signatures in
cases wild type for TP53 included MS4A1/CD20, LAX1, IGJ, PRF1,
DNAJB9, MOV10, LANCL2, CD2BP2 and IRF1. In the TP53-mutated
subgroup, STAT3 which is a BCL6 target gene was downregulated
in BLIMP-1− cases.32 Other unique signatures in DLBCL with
mutated TP53 included CFLAR, RBPJ, CMAH, DNAJC13, DLEU2,
VAMP5, and many others.
PRDM1 mutations within exon 1/2, but not mutations in exons
3–7, showed gene expression signatures
We further compared GEP between mutated and wild-type PRDM1
DLBCLs regardless of BLIMP-1 expression. In the overall DLBCL and
GCB subset, 103 and 193 DEGs were identiﬁed with FDR
thresholds of 0.10 and 0.05, respectively. No DEGs were identiﬁed
in the ABC subset, however, probably because of heterogeneity.
Similarly, GEP comparisons between cases with mutated PRDM1
exon 1/2 and those with wild-type PRDM1 only identiﬁed DEGs in
Table 3. BLIMP-1 protein expression and its correlation with pathologic and biological biomarkers in DLBCL
Variables Total ABC-DLBCL GCB-DLBCL Overall DLBCL
BLIMP-1+ BLIMP-1− P-value BLIMP-1+ BLIMP-1− P-value BLIMP-1 + BLIMP-1− P-value
Patient no. 520 n= 92 n= 158 n= 39 n= 229 n= 132 n= 388
ABC subtype 518 — — — — — — 70% (92/131) 41% (158/387) o0.0001
Ki-67⩾ 70% 516 76% (70/92) 65% (102/158) 0.066 56% (22/39) 60% (136/225) 0.72 71% (93/132) 62% (236/384) 0.092
BCL2 translocation 417 3.8% (3/80) 4% (5/127) 1.0 22% (8/36) 35% (60/173) 0.17 9% (11/116) 22% (65/301) 0.0043
Bcl-2⩾ 70% 514 55% (50/91) 59% (93/157) 0.60 28% (11/39) 47% (96/225) 0.11 47% (61/131) 49% (189/383) 0.61
MYC translocation 332 9% (6/70) 7% (7/101) 0.77 3% (1/30) 18% (24/130) 0.049 7% (7/100) 13% (31/232) 0.13
Myc⩾ 70% 513 31% (28/91) 42% (66/158) 0.085 18% (7/39) 29% (65/223) 0.15 28% (36/131) 34% (131/382) 0.15
BCL6 translocation 362 44% (30/69) 39% (39/101) 0.53 40% (12/31) 23% (36/159) 0.06 42% (42/101) 29% (75/261) 0.019
Bcl-6⩾ 50% 510 52% (47/90) 49% (77/157) 0.69 66% (26/39) 76% (171/224) 0.23 57% (73/129) 65% (248/381) 0.092
TP53 mutation 459 13% (10/80) 21% (30/142) 0.15 16% (6/38) 30% (59/198) 0.077 14% (16/118) 26% (89/341) 0.005
p53⩾ 20% 450 39% (31/80) 33% (46/139) 0.46 26% (10/38) 38% (75/193) 0.20 35% (41/118) 36% (121/332) 0.82
Wild-type p53⩾ 20% 348 36% (25/70) 20% (22/110) 0.024 28% (9/32) 26% (35/136) 0.82 33% (34/102) 23% (57/246) 0.049
Mutated p53⩾ 20% 102 60% (6/10) 83% (24/29) 0.20 17% (1/6) 70% (40/57) 0.017 44% (7/16) 74% (64/86) 0.02
p63⩾ 10% 499 51% (45/89) 41% (63/155) 0.15 53% (20/38) 38% (81/215) 0.10 51% (65/128) 39% (145/371) 0.023
MDM2410% 513 55% (50/91) 35% (24/156) 0.0018 46% (18/39) 34% (77/226) 0.15 52% (68/131) 34% (131/382) 0.0004
p2145% 450 40% (32/80) 28% (39/139) 0.074 42% (16/38) 19% (26/193) 0.0028 41% (48/118) 23% (75/332) 0.0003
IRF4/MUM1430% 515 84% (76/91) 73% (115/158) 0.054 35% (14/39) 22% (51/227) 0.062 69% (90/130) 43% (166/385) o0.0001
GCET1⩾ 50% 511 19% (17/90) 8% (13/155) 0.025 38% (15/39) 54% (122/226) 0.084 25% (32/129) 35% (133/382) 0.039
CD10430% 517 10% (9/92) 7% (11/158) 0.47 64% (25/39) 70% (159/228) 0.57 26% (34/131) 44% (170/386) 0.0003
Nuclear p65+ 467 66% (55/84) 50% (75/149) 0.028 62% (21/34) 61% (121/198) 1.0 65% (77/119) 56% (196/348) 0.13
Nuclear p50⩾ 20% 452 46% (36/79) 39% (55/141) 0.39 37% (13/35) 26% (50/196) 0.16 44% (50/115) 31% (105/337) 0.023
pAKT⩾ 30% 493 51% (45/88) 34% (51/151) 0.0095 51% (19/37) 37% (79/215) 0.1 51% (64/126) 35% (130/367) 0.0003
CD30+ 516 23% (21/92) 10% (15/156) 0.0082 18% (7/39) 16% (37/227) 0.82 21% (28/132) 14% (52/384) 0.05
Abbreviations: ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like. Bold values are the signiﬁcant P values or
those showing trends of signiﬁcance.
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Figure 4. Gene expression proﬁles for the overall and ABC-DLBCL patients and the BLIMP-1 network in DLBCL. (a) Differential expression of
genes between patients with and without homozygous PRDM1 deletions, and between patients with and without BLIMP-1 protein expression.
Differential expression of genes were only found between wild-type BLIMP-1+ and BLIMP-1− DLBCLs but not between mutated BLIMP-1+ and
BLIMP-1− DLBCLs. (b) A brief network of BLIMP-1’s functions and regulations summarizing our results. BLIMP-1 can be activated by p53, IRF4
and NF-κB signaling. BLIMP-1 represses the transcription of MYC, B-cell antigen/surface receptors and germinal center programs, whereas
activates LAX1, which inhibits BCR signaling; therefore, leading to attenuated BCR signaling and decreased tumor cell proliferation. BLIMP-1
also transactivates XBP1 and ELL2, which results in activation of plasmacytic differentiation and immunoglobulin production.
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the overall DLBCL (Supplementary Figure 5d and Supplementary
Table 5) and GCB (156 DEGs with an FDR threshold of 0.01) but not
ABC subset. Interestingly, tumor suppressors PTEN and IKZF1 (a
transcriptional regulator of lymphocyte differentiation) were
signiﬁcantly downregulated in cases with mutated PRDM1 exon
1/2. In contrast, no signiﬁcant genes were found differentially
expressed between cases with mutated PRDM1 exons 3–7 and
those with wild-type PRDM1.
DISCUSSION
In this study, we analyzed the clinical and experimental data on
520 de novo DLBCL cases to determine the tumor-suppressive
function of PRDM1/BLIMP-1. Previous studies demonstrated that
loss of PRDM1/BLIMP1 function is critical for the pathogenesis of
ABC-DLBCL.8,11 Herein, we provide evidence that loss of PRDM1/
BLIMP1 function is a factor for poor prognosis in ABC-DLBCL. We
found homozygous PRDM1 deletions and PRDM1mutations within
PRDM1 exons 1 and 2 were poor prognostic factors in patients
with ABC-DLBCL. Loss of BLIMP-1 protein expression was common
in ABC-DLBCL and associated with a decreased plasma-cell
differentiation signature and upregulation of B-cell antigens.
In univariate and multivariate analyses, we found that the
prognosis for DLBCL with homozygous PRDM1 deletion was worse
than that for DLBCL without this deletion. However, this
homozygous deletion only had prognostic signiﬁcance in the
ABC subgroup, as its impact on prognosis for GCB-DLBCLs was
minimal. Although the number of patients harboring homozygous
PRDM1 deletions was small, our GEP still supported reduced
transcriptional repression in patients with these deletions as
suggested by upregulation of transcription factors, including
ZNF385C, HLF and HMGA2. Notably, we only observed these gene
expression signatures in the ABC group.
Similarly, PRDM1 mutations only inﬂuenced survival of DLBCL in
the ABC subgroup. Our data further support this by demonstrating
that PRDM1mutations within exons 1 and 2 still signiﬁcantly affect
survival of ABC- but not GCB-DLBCLs. Therefore, we suggest that
intact BLIMP-1 function is critical for the repression of ABC-DLBCLs.
Exons 1 and 2 encode for the ﬁrst 97 amino acids of BLIMP-1,
including the N-terminal acidic domain. An intact N-terminal
acidic domain is critical for the normal transcriptional repression
function of BLIMP-1.33 Researchers showed that BLIMP-1 lacking
this domain do not repress the MYC promoter.34 Interestingly, all
but two of the PRDM1 mutations identiﬁed in our cohort were
missense mutations. Mandelbaum et al.11 proved that a subset of
missense mutations of PRDM1 can directly impair BLIMP-1’s
protein stability as well as its transcriptional repression function,
including 2 missense mutations at P48 (corresponding to 84P in
this article due to different transcripts), the most frequently
mutated site within exons 1 and 2 in our ABC-DLBCLs.11 Although
the decreased BLIMP-1 protein expression in patients with PRDM1
mutations within exons 1 and 2 was not signiﬁcant, we found that
mutations in exons 1 and 2 were closely correlated with Myc and
Bcl-2 co-expression, a previously identiﬁed marker for poor DLBCL
prognosis that was overrepresented in the ABC subgroup.18 GEP
analysis results reinforced the notion that BLIMP-1 mutations
especially those in exons 1-2 had lost functions of wild-type
BLIMP-1.
At the protein level, although BLIMP-1 expression was
frequently associated with the ABC phenotype of DLBCL, 63% of
the ABC-DLBCL patients lacked BLIMP-1 protein expression. Over
half of these BLIMP-1− ABC-DLBCL patients had no apparent
genetic changes in PRDM1. In vitro studies have demonstrated
that BLIMP-1 can be inactivated by constitutively active Bcl-6.9,11
We found a negative correlation between Bcl-6 and BLIMP-1
expression with borderline signiﬁcance. Also, expression of
BCL11A, a cofactor with Bcl-6, was upregulated in our GEP analysis
of both ABC and GCB subtypes of BLIMP-1− DLBCLs.35T
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Additionally, PRDM1 can be epigenetically regulated by diverse
miRNAs including miR-23, miR-9 and let-7a. 23–27 Using miRNA
proﬁling, we found upregulation of miR-30d and miR-30b-5p in
BLIMP-1− cases without genetic aberrations compared with
BLIMP1+ cases. Further functional evidence are needed to
elucidate the regulation between these miRNAs and BLIMP-1
expression.
ABC-DLBCL patients without expression of BLIMP-1 had
decreased expression of the tumor suppressor protein p53 and
its downstream targets MDM2 and p21, as well as increased
expression of Myc, which promotes cell proliferation.36 Therefore,
in BLIMP-1− DLBCL cases, decreased p53 signaling and Myc
overexpression may synergistically promote tumor progression. In
addition, loss of BLIMP-1 expression was associated with
dysregulation of NF-κB pathway molecules. Induction of PRDM1
mRNA expression in B-cell lymphoma cell lines can be blocked by
NF-κB inhibitors.37 Recently, Heise et al.38 proved that NF-κB
subunit p65 (RELA) is required for the induction of BLIMP-1
expression, which is consistent with the positive association of p65
expression and BLIMP-1+ in our ABC DLBCL cohort.
Surprisingly, BLIMP-1 protein expression was not a survival
predictor in the present study. Gyory et al.33 found that the
alternative splicing protein BLIMP-1β, which lacks the ﬁrst three
exons in the normal BLIMP-1 protein, does not have transcrip-
tional repression activity. Consistently, detection of BLIMP-1β
mRNA expression in tumor cells has been associated with poor
prognosis for ABC-DLBCL.39 Using our immunohistochemical
assay, we could not discriminate between the normal BLIMP-1
protein and BLIMP-1β. The presence of BLIMP-1β in our cohort
may reduce the prognostic impact of normal BLIMP-1 by
diminishing its ability to repress the activity of downstream
targets such as Myc and Bcl-6.
However, lack of BLIMP-1 expression seemed to be an
unfavorable prognostic factor for DLBCL in patients with aberrant
p53 statuses. Kusam et al.40 reported that Bcl-6 can immortalize
primary B cells and greatly increase B-cell function only in the
absence of normal p53 function. BLIMP-1 is a known transcrip-
tional repressor of BCL6.41 We found that BLIMP-1 positivity was
closely associated with the absence of Bcl-6 protein expression in
our group of DLBCL patients with mutated TP53. Therefore,
BLIMP-1 may inhibit the proliferation of tumor cells harboring
mutated TP53 by repressing Bcl-6 activity. Consistently, GEP
analysis in DLBCL patients with mutated TP53 found that
expression of IRF4 (an activator of BLIMP-1 and inhibitor of
BCL6) and STAT3 (a BCL6 target gene for repression),31,32 was
downregulated in the BLIMP-1− subgroup.
The BLIMP-1 negativity signature in the overall cohort of DLBCL
patients was similar to that in the ABC subgroup: both were
characterized by downregulation of plasmacytic differentiation
and upregulation of B-cell antigens. BLIMP-1’s role in promoting
plasmacytic differentiation27 of DLBCL was indicated by down-
regulation of XBP1 along with several of its downstream targets
involved in protein synthesis in endoplasmic reticulum and
transportation in BLIMP-1− cases.42 XBP1 is a transcriptional
activator that acts downstream of BLIMP-1. BLIMP-1 and XBP1
are jointly required for the establishment of terminally differ-
entiated plasma cells.28 Moreover, we found that expression of
genes involved in immunoglobulin production (ELL2, MZB1 and
ARID3A) and cell differentiation (BATF) was downregulated in the
BLIMP-1− group. On the other hand, loss of BLIMP-1 expression in
DLBCL correlated with upregulation of CD22 and BLK and
downregulation of LAX1 that have important roles in regulating
BCR signaling. Importantly, expression of MS4A1 (encoding CD20)
was also upregulated in BLIMP-1− cases, possibly indicating
an increased therapeutic effect of rituximab in patients with
BLIMP-1− DLBCL as suggested previously.43,44 In line with the role
of BLIMP-1 in plasmacytic differentiation suggested by GEP
analysis, the cell-of-origin analysis based on B-cell-associated
gene signatures22 also showed positive correlation between
BLIMP-1 expression and the plasmablastic subtype of DLBCL
(Table 1).
The antiproliferative effect of BLIMP-1 on DLBCL was also
suggested by the GEP results as cell-cycle suppressors (e.g.,
CDKN1B, GADD45A, GHITM, DUSP4) were upregulated in BLIMP-1+
DLBCLs. Also, in vitro experiments have demonstrated that B-cell
proliferation in DLBCL cell lines was promoted upon acute
ablation of BLIMP-1 and that BLIMP-1 inactivation led to B-cell
lymphomagenesis and shortening of life spans in mouse models
of DLBCL.8,11 Reintroduction of BLIMP-1 into a DLBCL cell line likely
represses the cells’ proliferation by turning off MYC and other
genes involved in cell-cycle progression and DNA repair.45 A brief
network of BLIMP-1’s functions and regulation generated from our
results is presented in Figure 4b.
Collectively, the results of the present study demonstrated that
loss of PRDM1/BLIMP-1 function contributed to the overall poor
prognosis for ABC-DLBCL in three ways. First, genetic PRDM1
aberrations (including homozygous deletions and mutations)
affected the prognosis for ABC- but not GCB-DLBCLs. Second, a
lack of BLIMP-1 expression correlated with an impaired p53
signaling pathway and Myc overexpression in ABC-DLBCLs. Third,
the GEP signatures of BLIMP-1 expression for the overall DLBCL
patient cohort resembled those for the ABC subgroup, both
indicating downregulation of plasmacytic differentiation of
DLBCLs and upregulation of B antigens and BCR signaling in
BLIMP-1− tumors. These data may suggest that inactivated
BLIMP-1 facilitates DLBCL progression through Myc and BCR
signaling, which are essential for survival of ABC-DLBCL.18,46
Therapeutic approaches that restore the normal function of
BLIMP-1 may help drive terminal differentiation of tumor cells and
overcome the chemoresistance of ABC-DLBCL.
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